Abstract: A method of reducing muscle damage in a human being includes providing an extract of Kenyan purple tea (scientific name: Camellia sinensis; variety name: TRFK306) containing 1,2-di-O-galloyl-4,6-O-(S)-hexahydroxydiphenoyl-?-D-glucose (GHG). Then, an effective amount of the purple tea extract is administered to a body of a human being engaged in intensive exercise to reduce muscle damage associated with the intensive exercise.

Abstract: A 5?-reductase inhibitor contains saw palmetto extract and seaberry extract as an active ingredient in a synergistic compounding ratio, wherein the compounding ratio by weight of the saw palmetto extract and the seaberry extract is 3:1˜2. The 5?-reductase inhibitor containing the saw palmetto extract and seaberry extract or just the seaberry extract as a 5?-reductase inhibitor can be administered to the human body in order to inhibit 5?-reductase. The 5?-reductase inhibitor is useful as a prostate enlargement inhibitor, an androgenic alopecia inhibitor, and an acne prevention and amelioration agent. The 5?-reductase inhibitor can be part of a food or drink composition or a cosmetic composition.

Abstract: An AMP-activated protein kinase (AMPK) activating agent comprises 1,2-di-O-galloyl-4,6-O—(S)-hexahydroxydiphenoyl-b-D-glucose (“GHG”) as an active ingredient. The AMPK activating agent can be a GHG-containing composition wherein the GHG is an active ingredient of the composition. The GHG-containing composition can be derived from Kenyan purple tea, whose scientific name is Camellia sinensis, variety name: TRFK306. An effective amount of the GHG can be administered to a cell to activate the AMPK. Drinks, foods, and cosmetics can have the GHG as an active ingredient.

Abstract: An AMP-activated protein kinase (AMPK) activating agent comprises 1,2-di-O-galloyl-4,6-O—(S)-hexahydroxydiphenoyl-b-D-glucose (“GHG”) as an active ingredient. The AMPK activating agent can be a GHG-containing composition wherein the GHG is an active ingredient of the composition. The GHG-containing composition can be derived from Kenyan purple tea, whose scientific name is Camellia sinensis, variety name: TRFK306. An effective amount of the GHG can be administered to a cell to activate the AMPK. Drinks, foods, and cosmetics can have the GHG as an active ingredient.

Abstract: A method of promoting NO-production in a human being includes providing an extract of Kenyan purple tea (scientific name: Camellia sinensis; variety name: TRFK306) containing 1,2-di-O-galloyl-4,6-O-(S)-hexahydroxydiphenoyl-?-D-glucose (GHG). Then, an effective amount of the purple tea extract is administered to a body of a human being in need of NO-production promotion.

Abstract: This invention provides a prophylactic and therapeutic agent for dry eye, having new ingredients to reduce the deterioration of the lacrimal secretory ability and to inhibit the generation of radical oxygen in lacrimal gland tissue. The prophylactic and therapeutic agent for dry eye of this invention contains the maqui berry extract as the active substance of this invention, i.e. containing delphinidin glycoside extracted from the maqui berry and at least one or more of the active substances delphinidin-3-sambubioside-5-glucoside, delphinidin-3,5-diglucoside, delphinidin-3-sambubioside and delphinidin-3-glucoside, preferably delphinidin-3,5-diglucoside.

Abstract: A method for activating energy metabolism in muscle cells by administering to human beings at least one active substance comprising methoxyflavone for energy metabolism activation, the at least one active substance shown in the following Chemical Formula 1, wherein for Chemical Formula 1, R1 means an alkyl group with the number of carbons being 1 and R2 is hydrogen, and neither the B-ring nor the C-ring of the flavone skeleton has a substituent The active substance can be part of a composition of food.

Abstract: The present disclosure relates to: an artificial peritoneal tissue comprising a cellular tissue and a mesothelial cell layer that covers the surface of the cellular tissue, wherein the cellular tissue comprises a fibroblast, an extracellular matrix, and a vascular endothelial cell and/or a lymphatic endothelial cell each capable of forming a lumen; and a method for producing the artificial peritoneal tissue.

Abstract: An air environment control system includes one or more adjustment devices that adjust an air environment in a space; and a control device that controls the one or more adjustment devices. The air environment control device includes an air environment control unit that controls (i) at least one of the one or more adjustment devices to create a cooler environment in the space, when a person does intellectual work in the space; and (ii) at least one of the one or more adjustment devices to create a warmer environment warmer than the cooler environment in the space, when the person has a break in the space. The control unit further controls at least one of the one or more adjustment devices to apply cool stimulation to the person, when the person starts the intellectual work in the space.

Abstract: An intellectual productivity evaluation device includes: an obtainment unit configured to obtain a set of answer times required by a subject to accomplish a task of answering a plurality of questions, the task being imposed on the subject as intellectual work; an evaluation unit configured to calculate an evaluation value related to a depth of concentration of the subject in a concentrated state using the set of answer times obtained by the obtainment unit based on a model in which the subject is in the concentrated state or an unconcentrated state during the intellectual work; and an output unit configured to output evaluation value information indicating the evaluation value calculated by the evaluation unit.

Abstract: Provided is an environment control system that controls an environment of a space in which a user performs an intellectual task. The environment control system includes: a controller which performs scene control for reproducing one or more predetermined scenes in the space by controlling one or more luminaires that emit illumination light that illuminates a predetermined area in the space and one or more air conditioning devices that air-condition the space. The one or more predetermined scenes include: a concentration scene that causes the user to concentrate on the intellectual task; and a rest scene that eases the concentration of the user. The controller switches between concentration scene control for reproducing the concentration scene and rest scene control for reproducing the rest scene when a predetermined condition is satisfied.

Abstract: This invention provides a new application to 1,2-di-O-galloyl-4,6-O—(S)-hexahydroxydiphenoyl-ß-D-glucose (i.e. GHG) that is contained in Kenyan purple tea (scientific name: Camellia sinensis; variety name: TRFK306), as well as a new circadian-rhythm regulator that can be widely used in medicines, foods and drinks, and cosmetics. The circadian-rhythm regulator of this invention is characterized in containing the GHG as an active ingredient for promoting the BMAL1 gene-expression. Also, the circadian-rhythm regulator of this invention is characterized in containing the GHG-content extract derived from Kenyan purple tea as an active ingredient for promoting the BMAL1 gene-expression.

Abstract: A method for activating metabolism for muscle cells involves administering an energy-metabolic activating agent to a human patient, the energy-metabolic activing agent as follows: (1) a sugar transporter (GLUT4) gene-expression promoting agent, including at least one active substance selected from the following: 5-hydroxy-3,7-dimethoxyflavone; techtochrysin; 3,7,4?-trimethylkaempferol; retusine; pentamethyiquercetin; trimethylapigenin; tetramethylkaempferol; and 5, 7-dimethoxyflavone, (2) a sugar transporter (GLUT4) gene-expression promoting agent, including at least one active substance selected from either techtochrysin or 5,7-dimethoxyflavone, and (3) a sugar transporter (GLUT4) gene-expression promoting agent within the muscle cells that includes any one of the chemical compounds shown in the following chemical formula 1. (Of such formula 1, R1 and R2, respectively, mean an alkyl group with hydrogen or with 1˜3-carbon.

Abstract: Provided is an environment control system that controls an environment of a space. The environment control system includes: a controller that performs scene control for reproducing one or more predetermined scenes in the space. The controller includes: a lighting controller that adjusts an illuminance or a color temperature of illumination light that is emitted by one or more luminaires and illuminates a predetermined area in the space, by controlling the one or more luminaires; and an air conditioning controller that adjusts a temperature, a humidity, and an airflow in the space by controlling one or more air conditioning devices that air-condition the space. The controller performs the scene control by adjusting the illuminance or the temperature of the illumination light, and the temperature, the humidity, and the airflow in the space.

Abstract: An intellectual-productivity analysis apparatus includes a presentation device, an input device, and an evaluation device. The presentation device presents a plurality of questions to a test subject. The input device allows the test subject input an answer to each question. The evaluation device includes a work memory part and an evaluating arithmetic part. The work memory part stores the answering time from a time when a question is presented on the presentation device to a time when the answer is inputted into the input device for each of the plurality of questions. The evaluating arithmetic part calculates an evaluation value on the intellectual productivity of the test subject during a measurement period of measuring the answering time of each of the plurality of questions by extracting a feature amount from the set of the answering time stored in the work memory part.

Abstract: This invention provides a new energy-metabolic activating agent for muscle cells and provides compounds that are widely used in foods and drinks and in medicines and in quasi-drugs or the like. The technical features of this invention are as follows: (1) A sugar transporter (GLUT4) gene-expression promoting agent, including at least one active substance selected from the following: 5-hydroxy-3,7-dimethoxyflavone; techtochrysin; 3,7,4?-trimethylkaempferol; retusine; pentamethylquercetin; trimethylapigenin; tetramethylkaempferol; and 5,7-dimethoxyflavone, (2) A sugar transporter (GLUT4) gene-expression promoting agent, including at least one active substance selected from either techtochrysin or 5,7-dimethoxyflavone, and (3) A sugar transporter (GLUT4) gene-expression promoting agent within the muscle cells that includes any one of the chemical compounds shown in the following chemical formula 1. (Of such formula 1, R1 and R2, respectively, mean an alkyl group with hydrogen or with 1˜3-carbon.